日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology
@NMSrheumatology
Followers
512
Following
39
Media
32
Statuses
140
Nippon Medical School/Dept. Rheumatology/Scleroderma and Myositis Center of Exellence (Prof. Masataka Kuwana). APLAR Center of Excellence.
*個別の医療相談には応じていません。
"Scleroderma: From Pathogenesis to Comprehensive Management" 3rd edition has been just published. Prof. Masataka Kuwana served on the editors.
#scleroderma
@SpringerClinMed
強皮症の専門書、待望の改訂第3版。 執筆陣はいずれも強皮症の著名な専門医。 桑名教授は編集者を務めました。
0
3
31
日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology
Dr. Akira Yoshida has presented his research data at a poster tour session in EULAR congress.
He has clarified the distinct cytokine profiles with elevated type I/III interferons in patients with anti-MDA5 antibody-positive dermatomyositis.
Hot topic🔥.
#EULAR2024
#皮膚筋炎
1
1
25
日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology
2023 ACR/CHEST Guideline for the Screening and Monitoring and Treatment of ILD in People With Systemic Autoimmune Rheumatic Diseases
📎 Downloadable flowcharts:
📄 Screening/Monitoring:
📄 Treatment:
(1 of 3)
1
19
51
0
1
24
日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology
Dr. Latika Gupta
@LatikaGupta_
, who is well known for her COVID-19 vaccination in autoimmune disease (COVAD) study, attended the JCR2023. We had a wonderful time having dinner together.
#4
当教室の出来事
#JCR2023
1
2
22
日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology
We are pleased to announce that our hospital has been selected as a Center of Excellence at APLAR 2023. Dr. Gono took the stage at the ceremony on behalf of our hospital. We would like to thank APLAR.
#APLAR23
#APLAR2023
0
4
18
日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology
日本リウマチ学会総会が開催中です。
4月18日、桑名正隆教授が「Meet the Expert 強皮症難治例ーケーススタディー」と題したsmall group discussionを行いました。難病の、難治例をいかに診療していくかのノウハウを学べるいい機会でした。
なお、予約券はもとより、当日券も即完売でした。
#JCR2024
0
1
16
日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology
This is not footnotes but quite important “Key Points” of the Treatment Algorithm
•Intended for Confirmed Group 1 PAH: Specifically for patients with mPAP ≥25 and PVR >3 with no significant response on acute vasoreactivity testing.
•Risk Assessment: Conduct baseline
0
5
15
0
1
17
日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology
8th Systemic Sclerosis World Congress has begun in Prague. It is very exciting.
At the opening ceremony, Prof. Kuwana was introduced as the editor-in-chief of JSRD, the journal on scleroderma.
#SystemicSclerosis
#SSWC2024
#JSRD
0
1
15
日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology
現在、グローバルの炎症性筋疾患の専門家では、抗合成酵素症候群(抗ARS抗体症候群)の分類基準を新規に策定するプロジェクト”The CLASS (Classification Criteria of Anti-Synthetase Syndrome) project”が進行中です。本研究成果は、本分類基準策定に際して重要な情報となります。
日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology
We would like to announce the renewal of World Scleroderma Foundation's website.
World Scleroderma Foundation
@Worldsclerofnd
は、強皮症研究者への研究費補助、強皮症国際学会のサポート、啓蒙活動を行っております。Websiteがリニューアルしました。#scleroderma
📣 Big Changes, Same Mission!
🌐 After months of dedication and hard work, we are proud to launch our redesigned website, a vital step in our journey of innovation and engagement with the scleroderma Community.
0
1
10
0
1
12
日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology
#EULAR2024
🚩>5000 abstracts.
-So much to learn.
-Try to pay attention to high quality abstracts.
🚩Abstract acceptance rate: 35%
-Oral 6.4%、Poster tour 8.6%、Poster view 20.2%.
🚩222 abstracts submissions from Japan. 🇯🇵
-Japan ranks higher on the list.
#JCR
Prof. Masataka Kuwana and Dr. Akira Yoshida are participating in the wonderful "CLASS project" from our center. We hope the project is successful. #EULAR2024
Oral presentation at
#EULAR2024
by Eduardo Dourado from Portugal on classification of anti-Synthetase Syndrome from
#CLASS
project. Spoke eloquently and made a complex topic easy.
0
4
46
0
0
11
日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology
Study found serum IFN-λ3 levels were significantly higher in PM/DM-associated ILD than in healthy controls
Levels were specifically increased in patients with anti-MDA5 antibody-positive DM-ILD and were associated with poor prognoses
In A&R
0
8
15
0
0
11
日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology
Two worldwide leaders in the field of Rheumatology, Prof. Rohit Aggarwal
@docrota
and Prof. Dinesh Khanna
@sclerodermaUM
, kindly attended the JCR2023. We had a great time having dinner together.
#4
当教室の出来事
#JCR2023
1
3
11
日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology
Dr. Akira Yoshida presented his findings on cytokine profiles in pts with anti-MDA5 ab+ dermatomyositis at GCOM meeting (left).
He is also a core member of “the CLASS project” and was actively engaged in lots of the research projects druing GCOM (right).
#GCOM2024
#myositis
0
1
9
日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology
Dr. Shinji Watanabe presented the difference of lung ultrasound findings between scleroderma and myositis. See photo.
Dr. Keina Yomono presented the prediction of scleroderma lung progression by combination of KL-6 and CRP/ESR.
#scleroderma
#ACR23
#ACR2023
#2
論文・学会発表
0
0
9
日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology
We have reported 7 antisynthetase syndrome patients who presented with digital ischemia.
🚩Digital ischemia is a rare and overlooked manifestation in antisynthetase syndrome.
🚩Angiographic findings are available in some cases.
🚩Systematic literature review was conducted.
A 68-yo woman presented with a 20-day history of exertional dyspnoea, acrocyanosis, & critical ischaemia of her fingers.
She also reported pain in the small joints of her hands & wrists and Raynaud's phenomenon in her fingers & toes.
Explore the case 👉
5
8
24
0
1
8
日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology
毎年開催されている、膠原病に伴う間質性肺疾患に関するWebinar、“4rd International Symposium on Interstitial Lung Disease in Rheumatic Diseases”のご案内です。1月12日から14日まで、毎日日本時間22時から26時半まで開催。登録は1月10日までです。
#5
膠原病トピックス
1
2
7
日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology
3 Highlighted Topics in GCOM2024
🚩“The CLASS project” is close to publication.
(The Classification Criteria of Anti-Synthetase Syndrome will be set.)
🚩2017 EULAR/ACR criteria for IIM revision work has begun.
🚩CAR T-cell therapy is highly effective for IIM.
#GCOM2024
#myositis
0
0
6
日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology
New Paper from “The CLASS (Classification Criteria of Anti-Synthetase Syndrome) project”
787 Serum Samples→Central immunoassay (RNA-IP etc) vs Local immunoassay→Comparison of anti-ARS ab detection
Jo-1 ab: very good agreement
Non Jo-1 ab: varied
New Full Length from Arthritis & Rheumatology:
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis
#OpenAccess
0
1
3
0
0
5
日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology
Dr. Anushka Aggarwal presented her survey work on the nomenclature of “anti synthetase syndrome”.
ASSD? ASS?
Thank you for taking the photo with Dr. Akira Yoshida (upper right).
#GCOM2024
#myositis
Day 1
#GCOM2024
: Personal meetings are much better than virtuals ones. Happy to finally meet the faces behind the screen. Also delighted to make new friends. 📸📸💜💜
0
2
22
0
0
5
日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology
We are pleased to inform that our center, Nippon Medical School, has been just selected as APLAR Center of Excellence for Research, Training and Education and Patient Care Award. We greatly appreciate it and hope to contribute to rheumatology in the Asia-Pacific region.
#APLAR
0
0
4
日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology
Fascinated by the GCOM session presenting differences in perspective of North American vs Asian experience with myositis-ILD! Would love to see South American perspective as well
#GCOM2024
#myositis
0
3
12
0
0
4
日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology
このたび、当施設はアジア太平洋リウマチ学会(APLAR)の中核的研究拠点(Center of Excellence)に選出されました。これまで日本からは4大学が選出されましたが、当施設は5番目に仲間入りさせていただけることになりました。国際的にもリウマチ学の発展に貢献できればと思います。
#4
当教室の出来事
日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology
We are pleased to inform that our center, Nippon Medical School, has been just selected as APLAR Center of Excellence for Research, Training and Education and Patient Care Award. We greatly appreciate it and hope to contribute to rheumatology in the Asia-Pacific region.
#APLAR
0
0
4
0
0
3
日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology
Prof. Kuwana was interviewed at the ACR meeting as the co-editor-in-chief of Journal of Scleroderma and Related Disorders (JSRD) journal, explaining the features of the journal. JSRD is a journal dedicated to scleroderma.
#Scleroderma
#JSRD
#ACR23
#ACR2023
2023年1月から3月にかけて、PhilippinesのRheumatologistであるDr. Francis Martin Cuencoが当科で臨床研修を行いました。一旦母国に帰国しましたが、日本リウマチ学会総会のAPLAR sessionに参加してくださり、うれしいことに再会できました。その一コマです(左から3番目)。
#4
当教室の出来事
#JCR2023
0
0
3
日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology